Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting
cyteir2018-03-07T22:46:02-05:00Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting -- Preclinical data elucidates mechanism and demonstrates successful intervention with small molecules in leukemia and lymphoid cancer models -- -- Clinical candidate expected to be identified in 2017 -- CAMBRIDGE, Mass. – March 28, [...]